Amplifying The Vaccines Of Tomorrow
At AdJane, we believe our OMV-Vacc platform technology will redefine vaccine development. Harnessing the natural power of Outer Membrane Vesicles (OMVs), we target diseases with highly unmet medical needs through our innovative vaccines and novel adjuvants. As a female-led company, we’re setting a new precedent in biotech beyond scientific innovation.
AdJane
AdJane was founded to fill a critical gap in the vaccine landscape: the need for safer, broadly protective, and efficient vaccines that do not rely on traditional aluminum adjuvants. Built around our novel OMV-Vacc platform, AdJane is advancing next-generation vaccines and adjuvants to combat critical global health challenges.
AdJane’s novel adjuvant technology
In the world of vaccines, we are revolutionizing the landscape with our innovative adjuvant technology. Our disruptive adjuvant products boost the potential and efficacy of vaccines, addressing critical healthcare challenges by enhancing the immune response. AdJane aims to reshape how vaccines are developed and delivered, providing enhanced protection against various diseases for people around the world.
What is an adjuvant?
An adjuvant is a crucial component of modern vaccines. It is a substance added to a vaccine to amplify the body’s immune response. By boosting the intensity of the response, adjuvants ensure that the immune system can recognize the vaccine’s components more effectively and remember them for longer periods of time, which may lead to a faster, longer-lasting and broader response of the immune system. Overall, the use of adjuvants enables vaccines to induce more persistent and potent immune responses, ensuring broader protection against infectious diseases.
OMV-Vacc Technology
Our Proprietary OMV-Vacc Platform Technology
Outer Membrane Vesicles (OMVs) are naturally released spherical nanoparticles found in gram-negative bacteria. These non-replicating vesicles carry strong immune potentiators such as PAMPs and trigger an immune response, enabling protective immunity.
AdJane has genetically engineered OMVs for enhanced safety, increased yield, and long term stability. Our unique OMV-Vacc platform, backed by 8 patent families, has been optimized for scalability and versatility, proven as we advance our programs along clinical development.
Combatting Antimicrobial Resistance and Neglected Disease
Our OMV technology has demonstrated an excellent safety profile in a Phase I clinical trial, is administration route-agnostic, scalable and stable over years. See our diversified pipeline of high impact programs for more information.
BEA
AdJane has developed BEA, a Gonorrhea vaccine based on its proprietary OMV-Vacc platform technology.
CARA
AdJane has developed a next-generation multivalent HFMD vaccine that offers broad protection against four distinct strains.
ADA
AdJane has developed its own adjuvants, ADA-24 and ADA-25, based on its proprietary OMV-Vacc platform technology.
News
